WO1998028625A1 - Verfahren zur diagnose und therapie von hodgkin-lymphomen - Google Patents
Verfahren zur diagnose und therapie von hodgkin-lymphomen Download PDFInfo
- Publication number
- WO1998028625A1 WO1998028625A1 PCT/EP1997/007081 EP9707081W WO9828625A1 WO 1998028625 A1 WO1998028625 A1 WO 1998028625A1 EP 9707081 W EP9707081 W EP 9707081W WO 9828625 A1 WO9828625 A1 WO 9828625A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- antibody molecule
- vlo
- exon
- amino acid
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 34
- 208000017604 Hodgkin disease Diseases 0.000 title claims abstract description 31
- 208000010747 Hodgkins lymphoma Diseases 0.000 title claims abstract description 21
- 208000021519 Hodgkin lymphoma Diseases 0.000 title claims abstract description 18
- 238000003745 diagnosis Methods 0.000 title claims abstract description 15
- 238000002560 therapeutic procedure Methods 0.000 title claims abstract description 14
- 230000014509 gene expression Effects 0.000 claims abstract description 35
- 101150017002 CD44 gene Proteins 0.000 claims abstract description 14
- 201000000306 sarcoidosis Diseases 0.000 claims abstract description 10
- 239000003147 molecular marker Substances 0.000 claims abstract description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 15
- 108060003951 Immunoglobulin Proteins 0.000 claims description 11
- 102000018358 immunoglobulin Human genes 0.000 claims description 11
- 230000002285 radioactive effect Effects 0.000 claims description 11
- 239000012634 fragment Substances 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 239000003053 toxin Substances 0.000 claims description 5
- 231100000765 toxin Toxicity 0.000 claims description 5
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 239000000824 cytostatic agent Substances 0.000 claims description 4
- 230000002519 immonomodulatory effect Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 229920001184 polypeptide Polymers 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 239000000651 prodrug Substances 0.000 claims description 4
- 229940002612 prodrug Drugs 0.000 claims description 4
- 230000001085 cytostatic effect Effects 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- 201000010099 disease Diseases 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 238000004393 prognosis Methods 0.000 abstract description 6
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 35
- 210000004027 cell Anatomy 0.000 description 33
- 102100032912 CD44 antigen Human genes 0.000 description 29
- 108020001507 fusion proteins Proteins 0.000 description 14
- 102000037865 fusion proteins Human genes 0.000 description 14
- 208000025275 nodular sclerosis classical Hodgkin lymphoma Diseases 0.000 description 14
- 108010058905 CD44v6 antigen Proteins 0.000 description 12
- 238000003752 polymerase chain reaction Methods 0.000 description 12
- 108010029485 Protein Isoforms Proteins 0.000 description 10
- 102000001708 Protein Isoforms Human genes 0.000 description 10
- 150000001413 amino acids Chemical group 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 8
- 230000009257 reactivity Effects 0.000 description 7
- 108700024394 Exon Proteins 0.000 description 6
- 238000010240 RT-PCR analysis Methods 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 210000001165 lymph node Anatomy 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 150000007523 nucleic acids Chemical class 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 210000004408 hybridoma Anatomy 0.000 description 5
- 230000002055 immunohistochemical effect Effects 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 238000010837 poor prognosis Methods 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 102000003992 Peroxidases Human genes 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- 229940072221 immunoglobulins Drugs 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 108040007629 peroxidase activity proteins Proteins 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 201000009030 Carcinoma Diseases 0.000 description 3
- 102000005720 Glutathione transferase Human genes 0.000 description 3
- 108010070675 Glutathione transferase Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 206010001488 Aggression Diseases 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- WESHVRNMNFMVBE-FXQIFTODSA-N Arg-Asn-Asp Chemical compound C(C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)O)N)CN=C(N)N WESHVRNMNFMVBE-FXQIFTODSA-N 0.000 description 2
- BWJZSLQJNBSUPM-FXQIFTODSA-N Asp-Pro-Asn Chemical compound OC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(O)=O BWJZSLQJNBSUPM-FXQIFTODSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- UPOJUWHGMDJUQZ-IUCAKERBSA-N Gly-Arg-Arg Chemical compound NC(=N)NCCC[C@H](NC(=O)CN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O UPOJUWHGMDJUQZ-IUCAKERBSA-N 0.000 description 2
- JMSONHOUHFDOJH-GUBZILKMSA-N His-Ser-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CN=CN1 JMSONHOUHFDOJH-GUBZILKMSA-N 0.000 description 2
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 2
- 108010092694 L-Selectin Proteins 0.000 description 2
- 102000010836 Lymphocyte Homing Receptors Human genes 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- YQYFYUSYEDNLSD-YEPSODPASA-N Val-Thr-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O YQYFYUSYEDNLSD-YEPSODPASA-N 0.000 description 2
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000016571 aggressive behavior Effects 0.000 description 2
- 208000012761 aggressive behavior Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 108010059459 arginyl-threonyl-phenylalanine Proteins 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 102000048851 human CD44 Human genes 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 1
- OMSKGWFGWCQFBD-KZVJFYERSA-N Ala-Val-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OMSKGWFGWCQFBD-KZVJFYERSA-N 0.000 description 1
- KMFPQTITXUKJOV-DCAQKATOSA-N Arg-Ser-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O KMFPQTITXUKJOV-DCAQKATOSA-N 0.000 description 1
- MOGMYRUNTKYZFB-UNQGMJICSA-N Arg-Thr-Phe Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MOGMYRUNTKYZFB-UNQGMJICSA-N 0.000 description 1
- MJIJBEYEHBKTIM-BYULHYEWSA-N Asn-Val-Asn Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N MJIJBEYEHBKTIM-BYULHYEWSA-N 0.000 description 1
- XXAMCEGRCZQGEM-ZLUOBGJFSA-N Asp-Ser-Asn Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O XXAMCEGRCZQGEM-ZLUOBGJFSA-N 0.000 description 1
- 101100505161 Caenorhabditis elegans mel-32 gene Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 101710108485 Envelope phospholipase F13 Proteins 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- XMPAXPSENRSOSV-RYUDHWBXSA-N Glu-Gly-Tyr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O XMPAXPSENRSOSV-RYUDHWBXSA-N 0.000 description 1
- WIKMTDVSCUJIPJ-CIUDSAMLSA-N Glu-Ser-Arg Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCN=C(N)N WIKMTDVSCUJIPJ-CIUDSAMLSA-N 0.000 description 1
- LCRDMSSAKLTKBU-ZDLURKLDSA-N Gly-Ser-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CN LCRDMSSAKLTKBU-ZDLURKLDSA-N 0.000 description 1
- GBYYQVBXFVDJPJ-WLTAIBSBSA-N Gly-Tyr-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)CN)O GBYYQVBXFVDJPJ-WLTAIBSBSA-N 0.000 description 1
- AFMOTCMSEBITOE-YEPSODPASA-N Gly-Val-Thr Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O AFMOTCMSEBITOE-YEPSODPASA-N 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101100059521 Homo sapiens CD44 gene Proteins 0.000 description 1
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 1
- MLSUZXHSNRBDCI-CYDGBPFRSA-N Ile-Pro-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)O)N MLSUZXHSNRBDCI-CYDGBPFRSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100022339 Integrin alpha-L Human genes 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- QNBVTHNJGCOVFA-AVGNSLFASA-N Leu-Leu-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCC(O)=O QNBVTHNJGCOVFA-AVGNSLFASA-N 0.000 description 1
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 1
- VEGLGAOVLFODGC-GUBZILKMSA-N Lys-Glu-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O VEGLGAOVLFODGC-GUBZILKMSA-N 0.000 description 1
- JHNOXVASMSXSNB-WEDXCCLWSA-N Lys-Thr-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O JHNOXVASMSXSNB-WEDXCCLWSA-N 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- HNFUGJUZJRYUHN-JSGCOSHPSA-N Phe-Gly-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC1=CC=CC=C1 HNFUGJUZJRYUHN-JSGCOSHPSA-N 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- BODDREDDDRZUCF-QTKMDUPCSA-N Pro-His-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@@H]2CCCN2)O BODDREDDDRZUCF-QTKMDUPCSA-N 0.000 description 1
- YDTUEBLEAVANFH-RCWTZXSCSA-N Pro-Val-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]1CCCN1 YDTUEBLEAVANFH-RCWTZXSCSA-N 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 241000242677 Schistosoma japonicum Species 0.000 description 1
- WTUJZHKANPDPIN-CIUDSAMLSA-N Ser-Ala-Lys Chemical compound C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CO)N WTUJZHKANPDPIN-CIUDSAMLSA-N 0.000 description 1
- RDFQNDHEHVSONI-ZLUOBGJFSA-N Ser-Asn-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O RDFQNDHEHVSONI-ZLUOBGJFSA-N 0.000 description 1
- TYYBJUYSTWJHGO-ZKWXMUAHSA-N Ser-Asn-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O TYYBJUYSTWJHGO-ZKWXMUAHSA-N 0.000 description 1
- WEQAYODCJHZSJZ-KKUMJFAQSA-N Ser-His-Tyr Chemical compound C([C@H](NC(=O)[C@H](CO)N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CN=CN1 WEQAYODCJHZSJZ-KKUMJFAQSA-N 0.000 description 1
- YUJLIIRMIAGMCQ-CIUDSAMLSA-N Ser-Leu-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YUJLIIRMIAGMCQ-CIUDSAMLSA-N 0.000 description 1
- VLMIUSLQONKLDV-HEIBUPTGSA-N Ser-Thr-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O VLMIUSLQONKLDV-HEIBUPTGSA-N 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- XSLXHSYIVPGEER-KZVJFYERSA-N Thr-Ala-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O XSLXHSYIVPGEER-KZVJFYERSA-N 0.000 description 1
- DJDSEDOKJTZBAR-ZDLURKLDSA-N Thr-Gly-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O DJDSEDOKJTZBAR-ZDLURKLDSA-N 0.000 description 1
- MEJHFIOYJHTWMK-VOAKCMCISA-N Thr-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)[C@@H](C)O MEJHFIOYJHTWMK-VOAKCMCISA-N 0.000 description 1
- HSQXHRIRJSFDOH-URLPEUOOSA-N Thr-Phe-Ile Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O HSQXHRIRJSFDOH-URLPEUOOSA-N 0.000 description 1
- FWTFAZKJORVTIR-VZFHVOOUSA-N Thr-Ser-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O FWTFAZKJORVTIR-VZFHVOOUSA-N 0.000 description 1
- BCYUHPXBHCUYBA-CUJWVEQBSA-N Thr-Ser-His Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O BCYUHPXBHCUYBA-CUJWVEQBSA-N 0.000 description 1
- AKHDFZHUPGVFEJ-YEPSODPASA-N Thr-Val-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O AKHDFZHUPGVFEJ-YEPSODPASA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- QHONGSVIVOFKAC-ULQDDVLXSA-N Tyr-Pro-His Chemical compound N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O QHONGSVIVOFKAC-ULQDDVLXSA-N 0.000 description 1
- DJEVQCWNMQOABE-RCOVLWMOSA-N Val-Gly-Asp Chemical compound CC(C)[C@@H](C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)O)N DJEVQCWNMQOABE-RCOVLWMOSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000004980 dosimetry Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000000267 erythroid cell Anatomy 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000012520 frozen sample Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 201000006585 gastric adenocarcinoma Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000011502 immune monitoring Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 230000002637 immunotoxin Effects 0.000 description 1
- 229940051026 immunotoxin Drugs 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 231100000608 immunotoxin Toxicity 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 230000008883 metastatic behaviour Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 210000004882 non-tumor cell Anatomy 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000011363 radioimmunotherapy Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000002784 sclerotic effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 108010020532 tyrosyl-proline Proteins 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
Definitions
- the present invention relates to methods for diagnosing and treating Hodgkin's lymphomas (Ly phogranulomatosis) which are based on the expression of the variant exon vlO of the CD44 gene as a molecular target, agents for these methods and the use of these agents
- the highly glycosylated cell surface protein CD44 is involved in the interaction between cells and the extracellular matrix such as migration and activation of leukocytes in inflammation and immune monitoring, precursors of leukocytic and myeloid cells in the bone marrow as well as the development of lymphoid organs and the interaction of cells with the extracellular Matrix involved (Lesley et al, 1993, Gunthert 1993, Pals et al, 1993, Mackay et al, 1994)
- the human CD44 gene is composed of at least 19 exons, of which at least 12 that code for the extracellular region are alternatively spliced (Screaton et al, 1992)
- the CD44 gene is transcribed in a number of normal tissues and carcinomas (Fox et al, 19 4), while the standard CD44 molecule (CD44s) is found ubiquitously expressed in epithelial and mesenchymal tissues different isoforms, which are generated by alternative RNA splicing, in a very restricted
- the object of the present invention was to develop new methods for the diagnosis and therapy of Hodgkin lymphomas (lymphogranulomatosis) and to provide means for such methods
- Hodgkin lymphomas lymphogranulomatosis
- Antibody molecules with a corresponding specificity are particularly suitable as Vehicle to selectively target Hodgkin's lymphomas in vivo
- the invention further relates to the use of an antibody molecule which is specific for an epitope within the amino acid sequence which is encoded by the variable exon vlO of the CD44 gene, for producing a pharmaceutical composition for the diagnosis and / or therapy of tumor diseases the tumor disease around Hodgkin's lymphoma (lymphogranulomatosis)
- the invention further relates to an antibody molecule which is specific for an epitope within the amino acid sequence which is encoded by the variable exon vlO of the CD44 gene, for pharmaceutical use.
- an antibody molecule is preferably characterized in that it binds to SEQ ID NO 2 In particular, act specifically as a monoclonal antibody, a Fab or F (ab ') 2 fragment of an immunoglobulin, a recombinantly produced antibody, a recombinantly produced chimeric or humanized antibody or single-chain antibody (scFv).
- Such an antibody molecule is preferred linked to a radioactive isotope, radioactive compound, enzyme, toxin, cytostatic, prodrug, cytokine or other immunomodulatory polypeptide
- nucleotide and amino acid sequence of the variant exon vlO of the CD44 gene is known (Screaton et al, 1992, Tolg et al, 1993). These sequences can be found in the sequence listing (SEQ ID NO 1 and 2). The existence of degenerate or allelic variants is for the implementation of the invention is not important, such variants are therefore expressly included
- the invention can be carried out with polyclonal or monoclonal antibodies which are specific for an epitope which is encoded by the exon vlO.
- the production of antibodies against known amino acid sequences can be carried out according to methods known per se (Catty, 1989).
- a peptide of this sequence can be synthesized and used as an antigen in an immunization protocol.
- Another way is to produce a fusion protein which contains the desired amino acid sequence by using a nucleic acid (which can be prepared synthetically or, for example, by polymerase chain reaction (PCR) from a suitable sample). , which codes for this sequence, is integrated into an expression vector and the fusion protein is expressed in a host organism.
- PCR polymerase chain reaction
- the optionally purified fusion protein can then be used as antigen in an immunization protocol and insert-specific antibodies or, in the case of monoclonal antibodies, hybridomas, which express insert-specific antibodies can be selected using suitable methods.
- Such methods are state of the art Heider et al. (1993, 1996) and Koopman et al. (1993) describe the production of antibodies against variant epitopes of CD44
- antibody molecules derived from poly- or monoclonal antibodies can also be used for the method according to the invention, for example Fab or F (ab ') 2 fragments of immunoglobulins, recombinantly produced single-chain antibodies (scFv), chimeric or humanized antibodies as well as other molecules that bind specifically to epitopes that are encoded by exon vlO.
- Fab or F (ab ') 2 fragments or other fragments can be generated from a complete immunoglobulin (Kreitman et al, 1993) furthermore able to produce recombinant VlO-specific antibody molecules. Corresponding methods are state of the art.
- Such recombinant antibody molecules can eg be humanized antibodies (Shin et al, 1989, Gussow et Seemann, 1991), bispecific antibodies (Weiner et al, 1993, Goodwin, 1989), single-chain antibodies (scFv, Johnson et Bird, 1991), complete or fragmentary immunoglobulins (Coloma et al, 1992, Nesbit et al, 1992, Barbas et al, 1992), or antibodies generated by chain shuffling (Winter et al, 1994).
- Humanized antibodies can be produced, for example, by CDR grafting (EP 0239400).
- Framework regions can also be produced Modifications (EP 0519596) Methods such as PCR (see B EP 0368684, EP 0438310, WO 9207075) or computer modeling (see B WO 9222653) can be used for the humanization of antibodies. Fusion proteins, for example swg / ec / z ⁇ zn, can also be used Antibody / toxin fusion proteins (Chaudhary et al, 1990, Friedman et al, 1993) are produced and used.
- the generic terms "antibodies” and “antibody molecules” are intended to include all polyclonal and monoclonal antibodies in this section Compounds fall, as well as other compounds that can be structurally derived from immunoglobulins and can be prepared by methods known per se
- antibody molecules can be used, for example, with radioactive isotopes such as 1 1 I, ⁇ In, 9 9 ⁇ v ⁇ / c o c j er radioactive compounds (Larson et al, 1991, Thomas et al, 1989, Srivastava, 1988), enzymes such as peroxidase or alkaline Phosphatase (Catty et Raykundalia, 1989), linked with fluorescent dyes (Johnson, 1989) or biotin molecules (Guesdon et al, 1979)
- IO-specific antibody molecules with radioisotopes such as 90 Y, ⁇ In, I31 I or 186 can be used Re (Quadri et al, 1993, Lenhard et al, 1985, Vriesendorp et al, 1991, Wilbur et al, 1989), toxins (Vitetta et al, 1991, Vitetta et Thorpe, 1991, Kreitman et al, 1993, Theuer
- the diagnostic method according to the invention can advantageously be used to examine samples from patients, for example from * biopsies, in whom Hodgkin's lymphoma (lymphogranulomatosis) is suspected or the diagnosis already exists but the tumor is to be characterized more precisely.
- Detection of variant CD44 -Molecules which contain an amino acid sequence which is encoded by the variable exon vlO can be carried out at the protein level by means of antibodies or at the nucleic acid level by means of specific nucleic acid probes or primers for the polymerase chain reaction (PCR).
- the invention accordingly also relates to antibody molecules and nucleic acids which are suitable as probes or primers for such methods, and the use of such antibodies and nucleic acids for the diagnosis and analysis of Hodgkin's lymphomas, for example Tissue sections can be examined immunohistochemically with antibodies using methods known per se. Extracts or body fluids obtained from tissue samples can also be examined using other immunological methods using antibodies, for example in Western blots, enzyme-linked immunosorbent assays (ELISA, Catty et Raykundalia, 1989), Radioimmunoassays (RIA, Catty et Murphy, 1989) or related immunoassays The tests can be qualitative, semi-quantitative or quantitative.
- the expression of the CD44 splice variant vlO in Hodgkin's disease is associated with aggressive behavior of the tumor and high risk of recurrence. It correlates with advanced stage and poor prognosis of NSHD (nodular sclerosis Hodgkin's disease)
- antibody molecules with specificity according to the invention are also suitable for the diagnosis of Hodgkin's lymphomas.
- the label can be detected for diagnostic purposes, for example visualization of the tumor in vivo (imaging, or, for example, for radio-assisted surgery (radwguided surgety), for the use of antibodies conjugated with radioactive isotopes for immunoscintigraphy (imagingJ, for example, there are a number of protocols on the basis of which the person skilled in the art can carry out the invention ( Siccardi et al, 1989, Keenan et al, 1987, Perkins et Pimm, 1992, Colcher et al, 1987, Thompson et al, 1984)
- Data obtained by detecting and / or quantifying the expression of the variant CD44 epitope vlO can thus be incorporated into the diagnosis and prognosis.
- the combination with other prognostic parameters, for example with the degree of tumor, can be advantageous
- Antibody molecules with the specificity according to the invention and possibly linked to a cytotoxic agent can advantageously be used for the therapy of Hodgkin lymphomas (lymphogranulomatosis).
- the application can be systemic or topical, for example intravenous (as a bolus or continuous infusion), intraperitoneal, intramuscular Subcutaneous injection or infusion protocols for the administration of conjugated or non-conjugated antibodies (whether as complete immunoglobulins, fragments, recombinant humanized molecules or the like) are state of the art (Mulshine et al, 1991, Larson et al, 1991, Vitetta et Thorpe, 1991 , Vitetta et al, 1991, Breitz et al, 1992, 1995, Press et al, 1989, Weiner et al, 1989, Chatal et al, 1989, Sears et al, 1982)
- the antibody molecules can be formulated in a manner known per se.
- the antibody molecules can be present, for example, in an aqueous solution which may be buffered with a physiologically acceptable buffer. Such a solution can be characterized by the addition of suitable stabilizers and auxiliary substances.
- the antibody molecules can also be in the form of a freeze-dried preparation ( Lyophyllisate) are present, which is reconstituted with a suitable solvent, e.g. water, before use
- a preferred embodiment of a therapeutic application consists of a humanized vlO-specific immunoglobulin or an F (ab ') 2 fragment thereof with 90 Y (Quadri et al, 1993, Vriesendorp et al, 1995), 131 I (Juweid et al, 1995, Press et al, 1995, Thomas et al, in Catty 1985, p.
- 186 Re (Breitz et al, 1992, 1995) or another suitable radioisotope and to use them for radioimmunotherapy of Hodgkin's lymphomas
- an antibody molecule can be linked to 90 Y using a chelating linker such as ITCB-DTPA (isothiocyanatobenzyl-diethylenetriaminepentaacteate), a specific activity of 5-20 mCi / mg, preferably 10 mCi / mg should be achieved -positive tumor in a dosage of 0 1 to 1 mCi / kg body weight, preferably 0 3 to 0 5 mCi / kg body weight, particularly preferably 0 4 mCi / kg, given a total to be administered Protein amount of 2 to 5 mg can be done in the form of a rapid intravenous bolus injection.
- ITCB-DTPA isothiocyanatobenzyl-diethylenetriaminepentaacteate
- Fig. 1 A. Single HRS (Hodgkin and Reed-Sternberg) cell of a patient without recurrence, which reacts with mAb VFF16 (CD44vlO) arrowheads point to non-reactive HRS cells B.> 50% of the HRS cells from patients with relapse show reactivity (ABC, x 400)
- the entire variant region of the HPKII type of CD44v was amplified from human keratinocyte cDNA by polymerase chain reaction (PCR).
- PCR polymerase chain reaction
- the two PCR primers 5 '-CAGGCTGGGAGCCAAATGAAGAAAATG-3 ' , positions 25-52, and 5 -TGATAAGGAACGATTGACATTAGAGTTGGA-3 ', positions 1013-984 of the LCLC97 variant region as described by Hofmann et al. contained an EcoRI recognition site that was used to clone the PCR product directly into the vector ⁇ GEX-2T (Smith et al, 1988).
- the resulting construct (pGEX CD44v HPKII, v3-vl0) encoded a fusion protein of ⁇ 70 kD, consisting of glutathione-S-transferase from Schistosoma japonicum and exons v3-vl0 from human CD44 (Heider et al, 1993).
- the fusion protein was expressed in E. coli and then affinity-purified using glutathione-agarose (Smith et al, 1988)
- mice Female Balb / c mice were immunized intraperitoneally with the affinity-purified fusion protein according to the following scheme
- the immunizations were carried out at intervals of 4 weeks. 14 days after the last immunization, the animals were immunized for three consecutive days with 10 ⁇ g of fusion protein in PBS on the following day Polyethylene glycol 4000 fused The hybridoma cells were then selected in microtiter plates in HAT medium (Kohler et Milstein, 1975, Kearney et al, 1979)
- the determination of the antibody titer in the serum or the screening of the hybridoma supernatants was carried out with the aid of an ELISA.
- microtiter plates were first coated with fusion protein (GST-CD44v3-10) or only with glutathione-S-transferase, followed by serial dilutions incubated with serum samples or hybridomas and the specific antibodies were detected with peroxidase-conjugated antibodies against mouse immunoglobulin. Hybridomas that only reacted with glutathione-S-transferase were discarded.
- Antibodies from the supernatants of the hybrid domains VFF-14 and VFF-16 only bind to fusion proteins which contain a domain which is encoded by the exon vlO
- the lymph node samples were stained with the following mAbs CD44 standard (s) recognized by mAb SFF2, CD44v5 detected by mAb VFF8, CD44v6 detected by mAbs VFF7 and VFF18, CD44vlO detected by mAbs VFF14 and VFF16 MAb SFF2 recognized an epitope that Common to all CD44 isoforms MAbs VFF7 and VFF18 recognize different but overlapping epitopes that are encoded by exon v6 MAb VFF8 is specific to exon v5 MAbs VFF14 and VFF16 react with an epitope that is encoded by exon vlO
- CD44 expression patterns were analyzed using the Pearson-chi-square calculation and the Mantel-Haenszel test for linear association using the SPSS for Windows program P values that were equal to or less than 0 05 , were considered significant
- Table 1 shows an overview of the results obtained with antibodies directed against CD44s, CD44v5, v6 and v10 in HRS cells.
- the majority of the antigenic reactivity of the HRS cells was in all cases on the cell surface giving a variable number of HRS cells cytoplasmic and / or point-like perinuclear reactivity with or without surface staining, which are likely to reflect the reactivity of CD44 molecules in the Golgi apparatus or in the endoplasmic reticulum
- CD44vlO detected by mAbs VFF14 and VFF16
- CD44- mAbs can also be applied to paraffin embedded material when microwave treatment is used. This procedure requires constant fixation and microwave treatment to give reproducible results.
- CD44v6 positive and we could not find any correlation with the prognosis using two different antibodies to CD44v6. Because these two mAbs used against v6 recognize different epitopes of the exon v6-encoded amino acid sequence, this lack of detectable CD44v6 in most cases (see Table 1) cannot be explained by modification or masking of epitopes. In contrast to the frequent expression of CD44v5 in gastric adenocarcinomas (Heider et /., 1993), the data regarding CD44v5 expression were not statistically significant within the three groups of NSHD.
- Exon vlO is - in addition to exons v3 and v6 - a variant exon that is constitutively expressed in lymphocytes (Stauder et al, 1994). So far, CD44v10 expression in NHLs has not been systematically analyzed, and this exon has rarely been detected in carcinomas (Heider et al, 1996).
- VFF14 and VFF16 two different antibodies against CD44vlO
- the present invention demonstrates a statistically significant upregulation of CD44vlO expression in HRS cells from NSHD with poor prognosis (groups 2 and 3). Both exon vlO-specific antibodies showed identical results both on the surface and (and / or) in the cytoplasm of the HRS cells.
- CD44v10 expression with 2 different mAbs is important because, for example, in breast cancer, divergent data were obtained from different authors using different mAbs with the same exon specificity (Friedrichs et al, 1995, Kaufmann et al, 1995). To further confirm our surprising results, all cases were independently immunostained in a different laboratory (using a different staining method), with identical results.
- RT-PCR reverse transcriptase polymerase chain reaction
- RNA 1 ⁇ g of total RNA was isolated and reverse transcribed, as described in the literature (Gunthert et ⁇ /., 1991) 5 ⁇ l first-strand cDNA was amplified with Taq polymerase (Promega, Madison, USA) in a volume of 50 ⁇ l , using the buffer conditions recommended by the manufacturer. The primer concentration was 0 2 mM.
- a GAPDH-PCR with oligonucleotides homologous to positions 8-29 and 362 was carried out - 339 of the published GAPDH cDNA sequence (Allen et /., 1987) were carried out.
- the RT-PCR analysis confirmed the expression of CD44 isoforms containing CD44vlO (since these are only recently obtained samples, the further course of the disease in these patients is not yet known)
- the amplified fragments correspond to CD44 transcripts which have the constant proportion of CD44 in combination with the variant exon vlO (460 bp band) or variant exon vlO plus further variant exons (660 bp band) (FIG. 3, right half) )
- cDNAs were amplified in parallel with primers specific for the 5 'and 3' constant region of CD44 (Fig.
- Quadri SM Quadri SM, Vriesendorp HM, Leichner PK, Williams J R. Evaluation of indium- 1 11 and yttrium-90 labeled linker immunoconjugates in nude mice and dogs. J. Nucl Med. 34: 938-945 (1993). Ristamäki R, Joensuu H, Salmi M, Jalkanen S Serum CD44 in malignant lymphoma an association with treatment response Blood 84 (1): 238-243 (1994)
- Senter PD Schreiber GJ, Hirschberg DL, Ashe SA, Hellstrom KE, Hellstrom I Enhancement of the in vitro and in vivo antitumor activities of phosphorylated mitomyein C and etoposide derivatives by monoclonal antibody-alkaline phosphatase conjugates. Cancer Res. 49: 5789-5792 (1989).
- lymphocyte molecule implicated in lymph node homing is a member of the cartilage link protein family. Cell 56 (6): 1057-1062 0 (1989).
- CD44 variant isoforms are preferentially expressed in basal epithelial of non-malignant human fetal and adult tissues. Histochemistry 101 30 (2): 79-89 (1994).
- Weiner LM Holmes M, Adams GP, LaCreta F, Watts P, Garcia de Palazzo I. A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16. Cancer Res. 53 (1): 94-100 (1993). Weiner LM, Holmes M, Richeson A, Godwin A, Adams GP, Hsieh-Ma ST, Ring DB, Alpaugh RK. Binding and cytotoxicity characteristics of the bispecific murine monoclonal antibody 2B1. J. Immunol 151 (5): 2877-2886 (1993).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/331,254 US6372441B1 (en) | 1996-12-20 | 1997-12-17 | Method for diagnosis and therapy of Hodgkin's lymphomas |
CA002272855A CA2272855A1 (en) | 1996-12-20 | 1997-12-17 | Method of diagnosis and therapy of hodgkin's lymphomas |
EP97954412A EP0946880A1 (de) | 1996-12-20 | 1997-12-17 | Verfahren zur diagnose und therapie von hodgkin-lymphomen |
JP52834198A JP2001508052A (ja) | 1996-12-20 | 1997-12-17 | ホジキンリンパ腫(Hodgkin’s lymphoma)の診断および治療方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19653607.3 | 1996-12-20 | ||
DE19653607A DE19653607A1 (de) | 1996-12-20 | 1996-12-20 | Verfahren zur Diagnose und Therapie von Hodgkin-Lymphomen |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/331,254 A-371-Of-International US6372441B1 (en) | 1996-12-20 | 1997-12-17 | Method for diagnosis and therapy of Hodgkin's lymphomas |
US10/052,641 Continuation US20030032073A1 (en) | 1996-12-20 | 2002-01-23 | Method for diagnosis and therapy of Hodgkin's lymphomas |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998028625A1 true WO1998028625A1 (de) | 1998-07-02 |
Family
ID=7815732
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1997/007081 WO1998028625A1 (de) | 1996-12-20 | 1997-12-17 | Verfahren zur diagnose und therapie von hodgkin-lymphomen |
Country Status (6)
Country | Link |
---|---|
US (2) | US6372441B1 (de) |
EP (1) | EP0946880A1 (de) |
JP (1) | JP2001508052A (de) |
CA (1) | CA2272855A1 (de) |
DE (1) | DE19653607A1 (de) |
WO (1) | WO1998028625A1 (de) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19911329A1 (de) * | 1998-03-27 | 2000-09-21 | Benes Ivan Friedrich | Humantherapeutisch anwendbares Radioimmunkonjugat und Verfahren zu seiner Herstellung |
US8071072B2 (en) | 1999-10-08 | 2011-12-06 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
US20090004103A1 (en) * | 1999-10-08 | 2009-01-01 | Young David S F | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
US20050100542A1 (en) * | 1999-10-08 | 2005-05-12 | Young David S. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
US7947496B2 (en) * | 1999-10-08 | 2011-05-24 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
US8048416B2 (en) | 1999-10-08 | 2011-11-01 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
US20080124327A1 (en) * | 1999-10-08 | 2008-05-29 | Arius Research, Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
US20030077590A1 (en) * | 2000-09-22 | 2003-04-24 | Pedersen Finn Skou | Methods for diagnosis and treatment of diseases associated with altered expression of neurogranin |
US20030044803A1 (en) * | 2000-09-22 | 2003-03-06 | Pedersen Finn Skou | Methods for diagnosis and treatment of diseases associated with altered expression of JAK1 |
US20070098728A1 (en) * | 2001-09-24 | 2007-05-03 | Pedersen Finn S | Novel compositions and methods in cancer |
US20040110933A1 (en) * | 2002-09-13 | 2004-06-10 | Dyax Corporation | CD44-binding ligands |
US20050009110A1 (en) * | 2003-07-08 | 2005-01-13 | Xiao-Jia Chang | Methods of producing antibodies for diagnostics and therapeutics |
JP5960793B2 (ja) * | 2011-03-24 | 2016-08-02 | ニューリム ファーマシューティカルズ(1991)リミテッド | 神経保護ペプチド |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0538754A2 (de) * | 1991-10-23 | 1993-04-28 | Forschungszentrum Karlsruhe GmbH | Verwendung von Antikörper enthaltenden Präparationen zur Immunsuppression |
WO1994002633A1 (en) * | 1992-07-21 | 1994-02-03 | Isis Innovation Limited | Diagnostic method |
WO1995000851A1 (de) * | 1993-06-22 | 1995-01-05 | Boehringer Ingelheim International Gmbh | Verfahren zur diagnose und analyse von tumoren |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4014510A1 (de) | 1990-05-07 | 1991-11-14 | Kernforschungsz Karlsruhe | Variante cd44-oberflaechenproteine, diese kodierende c-dna-sequenzen, antikoerper gegen diese proteine sowie ihre verwendung in der diagnostik und therapie |
WO1994012631A1 (en) | 1992-11-20 | 1994-06-09 | Isis Innovation Limited | Peptide corresponding to cd44 exon 6, antibodies specific for said peptide and use of these antibodies for diagnosis of tumors |
WO1995000658A1 (en) | 1993-06-18 | 1995-01-05 | Sirpa Jalkanen | COMPOSITIONS AND DIAGNOSTIC METHODS USING MONOCLONAL ANTIBODIES AGAINST CD44v6 |
-
1996
- 1996-12-20 DE DE19653607A patent/DE19653607A1/de not_active Withdrawn
-
1997
- 1997-12-17 CA CA002272855A patent/CA2272855A1/en not_active Abandoned
- 1997-12-17 US US09/331,254 patent/US6372441B1/en not_active Expired - Fee Related
- 1997-12-17 WO PCT/EP1997/007081 patent/WO1998028625A1/de not_active Application Discontinuation
- 1997-12-17 JP JP52834198A patent/JP2001508052A/ja active Pending
- 1997-12-17 EP EP97954412A patent/EP0946880A1/de not_active Withdrawn
-
2002
- 2002-01-23 US US10/052,641 patent/US20030032073A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0538754A2 (de) * | 1991-10-23 | 1993-04-28 | Forschungszentrum Karlsruhe GmbH | Verwendung von Antikörper enthaltenden Präparationen zur Immunsuppression |
WO1994002633A1 (en) * | 1992-07-21 | 1994-02-03 | Isis Innovation Limited | Diagnostic method |
WO1995000851A1 (de) * | 1993-06-22 | 1995-01-05 | Boehringer Ingelheim International Gmbh | Verfahren zur diagnose und analyse von tumoren |
Non-Patent Citations (5)
Title |
---|
ERMAK, G. ET AL.: "Restricted patterns of CD44 variant exon expression in human papillary thyroid carcinoma", CANCER RESEARCH, vol. 56, 1 March 1996 (1996-03-01), pages 1037 - 1042, XP002063388 * |
GHAFFARI, S. ET AL.: "Differentation-associated changes in CD44 isoform expression during normal hematopoiesis and their alteration in chroninc meyloid lekemia.", BLOOD, vol. 86, no. 8, 1995, pages 2976 - 2985, XP002063386 * |
JACKSON, D. G. ET AL.: "Multiple variants of the human lymphocyte homing receptor CD44 generated by insertions at a single site in the extracellular domain", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 267, no. 7, 1992, pages 4732 - 4739, XP002063387 * |
SCREATON G R ET AL: "THE IDENTIFICATION OF A NEW ALTERNATIVE EXON WITH HIGHLY RESTRICTEDTISSUE EXPERESSION IN TRANSCRIPTS ENCODING THE MOUSE PGP -1 (CD44) HOMING RECEPTOR", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 268, no. 17, 15 June 1993 (1993-06-15), pages 12235 - 12238, XP000470181 * |
TOLG C ET AL: "SPLICING CHOICE FROM TEN VARIANT EXONS ESTABLISHES CD44 VARIABILITY", NUCLEIC ACIDS RESEARCH, vol. 21, no. 5, 11 March 1993 (1993-03-11), pages 1225 - 1229, XP000508272 * |
Also Published As
Publication number | Publication date |
---|---|
US20030032073A1 (en) | 2003-02-13 |
JP2001508052A (ja) | 2001-06-19 |
US6372441B1 (en) | 2002-04-16 |
CA2272855A1 (en) | 1998-07-02 |
EP0946880A1 (de) | 1999-10-06 |
DE19653607A1 (de) | 1998-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0765343B1 (de) | MONOKLONALER ANTIKÖRPER GEGEN CD44v6 | |
WO1998028625A1 (de) | Verfahren zur diagnose und therapie von hodgkin-lymphomen | |
US8946390B2 (en) | Cancer-associated antigen | |
KR20230035697A (ko) | 암 진단에 유용한 클라우딘 18.2에 대한 항체 | |
US6010865A (en) | Process for detecting a variant CD44 gene product | |
EP0865609B1 (de) | Verfahren zur diagnose und therapie von plattenepithelkarzinomen | |
WO1995004547A1 (de) | DURCH EXON v5 DES CD44-GENS KODIERTE POLYPEPTIDE ALS TARGETS FÜR IMMUNTHERAPIE UND IMMUNSZINTIGRAPHIE VON TUMOREN | |
EP0585570B1 (de) | Granulozytenbindende Antikörperkonstrukte, ihre Herstellung und Verwendung | |
MXPA99005544A (es) | Molecula de anticuerpo y su empleo para la diagnosis y terapia de linfomas de hodgkin | |
DE19545472A1 (de) | Verfahren zur Diagnose und Therapie von Plattenepithelkarzinomen | |
DE4431297A1 (de) | Monoklonaler Antikörper gegen CD44v6 | |
MXPA96006108A (es) | Anticuerpos monoclonales contra cd44v6 | |
DE60223677T2 (de) | Bcmp-101, ein mit krebs assoziiertes protein | |
DE4414787A1 (de) | Verfahren zur Diagnose und Analyse von Zervixkarzinomen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP MX US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1997954412 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2272855 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1999/005544 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 1998 528341 Kind code of ref document: A Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 1997954412 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09331254 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997954412 Country of ref document: EP |